Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis

British Journal of Clinical Pharmacology

Volumn 79, Issue 2, 2015, Pages 286-297

  Ternant, David ^a,b   Ducourau, Emilie ^a,b   Fuzibet, Piéra ^a,b   Vignault, Céline ^a,b   Watier, Hervé ^a,b   Lequerré, Thierry ^c,d   Le Loët, Xavier ^c,d   Vittecoq, Olivier ^c,d   Goupille, Philippe ^a,b   Mulleman, Denis ^a,b   Paintaud, Gilles ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

^c UNIVERSITÉ DE ROUEN   (France)

^d ROUEN UNIVERSITY HOSPITAL   (France)

Author keywords

adalimumab; pharmacodynamics; pharmacokinetic pharmacodynamic modelling; pharmacokinetics; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONCENTRATION AT STEADY-STATE; DAS28; DISEASE ACTIVITY SCORE; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG EFFICACY; ELIMINATION HALF-LIFE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FALSE NEGATIVE RESULT; FEMALE; HUMAN; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LOADING DRUG DOSE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; QUALITY CONTROL; RHEUMATOID ARTHRITIS; TIME TO MAXIMUM PLASMA CONCENTRATION; VISUAL ANALOG SCALE; VOLUME OF DISTRIBUTION; ARTHRITIS, RHEUMATOID; BIOLOGICAL MODEL; CLINICAL TRIAL; COMPUTER SIMULATION; DOSE RESPONSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TISSUE DISTRIBUTION; YOUNG ADULT;

ADALIMUMAB; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; TIME FACTORS; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84941091583     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12509     Document Type: Article

References (35)

1. FDA. Adalimumab indications and usage. Accessed at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm092762.pdf (last accessed 16 October 2014). 2011.
2. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ,. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011; 305: 1460-1468.
3. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ,. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-926.
4. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P,. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591.
5. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischkoff S, Kupper H,. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004; 63: 508-516.
6. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM,. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther 2011; 33: 946-964.
7. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, Davis HM, Zhou H,. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009; 65: 1211-1228.
8. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G,. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006; 28: 169-174.
9. Ternant D, Mulleman D, Lauféron F, Vignault C, Ducourau E, Wendling D, Goupille P, Paintaud G,. Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis. Br J Clin Pharmacol 2012; 73: 55-65.
10. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H,. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-695.
11. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK,. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther 2003; 25: 1700-1721.
12. FDA. Adalimumab Product Approval Information-Licensing Action 12/31/02. Accessed at http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm092762.pdf (last accessed 12 February 2013). 2002.
13. Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P,. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-1640.
14. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, Bendtzen K,. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009; 68: 1739-1745.
15. Blache C, Lequerre T, Roucheux A, Beutheu S, Dedreux I, Jacquot S, Le Loet X, Boyer O, Vittecoq O,. Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept. Rheumatology 2011; 50: 1814-1822.
16. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL,. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 34-40.
17. Ait-Oudhia S, Lowe PJ, Mager DE,. Bridging clinical outcomes of canakinumab treatment in patients with rheumatoid arthritis with a population model of IL-1β kinetics. CPT Pharmacometrics Syst Pharmacol 2012; 2012: 6.
18. Chiu YL, Rubin DT, Vermeire S, Louis E, Robinson AM, Lomax KG, Pollack PF, Paulson SK,. Serum adalimumab concentration and clinical remission in patients with Crohn's disease. Inflamm Bowel Dis 2013; 19: 1112-1122.
19. Jürgens M, Mahachie John JM, Cleynen I, Schnitzler F, Fidder H, van Moerkercke W, Ballet V, Noman M, Hoffman I, van Assche G, Rutgeerts PJ, van Steen K, Vermeire S,. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421-427.
20. Magro F, Rodrigues-Pinto E, Santos-Antunes J, Vilas-Boas F, Lopes S, Nunes A, Camila-Dias C, Macedo G,. High C-reactive protein in Crohn's disease patients predicts nonresponse to infliximab treatment. J Crohns Colitis 2014; 8: 129-136.
21. Kravitz MS, Shoenfeld Y,. Autoimmunity to protective molecules: is it the perpetuum mobile (vicious cycle) of autoimmune rheumatic diseases? Nat Clin Pract Rheumatol 2006; 2: 481-490.
22. Puchalski T, Prabhakar U, Jiao Q, Berns B, Davis HM,. Pharmacokinetic and pharmacodynamic modeling of an anti-interleukin-6 chimeric monoclonal antibody (siltuximab) in patients with metastatic renal cell carcinoma. Clin Cancer Res 2010; 16: 1652-1661.
23. Urien S, Bardin C, Bader-Meunier B, Mouy R, Compeyrot-Lacassagne S, Foissac F, Florkin B, Wouters C, Neven B, Treluyer JM, Quartier P,. Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes. BMC 2013; 14: 40.
24. Pepys MB, Hirschfield GM,. C-Reactive protein: a critical update. J Clin Invest 2003; 111: 1805-1812.
25. Levi M, Grange S, Frey N,. Exposure-response relationship of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in a large population of patients with rheumatoid arthritis. J Clin Pharmacol 2013; 53: 151-159.
26. Comets E, Brendel K, Mentre F,. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-166.
27. Hayashi N, Tsukamoto Y, Sallas WM, Lowe PJ,. A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. Br J Clin Pharmacol 2007; 63: 548-561.
28. Lowe PJ, Tannenbaum S, Gautier A, Jimenez P,. Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. Br J Clin Pharmacol 2009; 68: 61-76.
29. Ng CM, Joshi A, Dedrick RL, Garovoy MR, Bauer RJ,. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm Res 2005; 22: 1088-1100.
30. Ng CM, Bruno R, Combs D, Davies B,. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. J Clin Pharmacol 2005; 45: 792-801.
31. Dirks NL, Meibohm B,. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010; 49: 633-659.
32. Mori S,. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. Mod Rheumatol 2007; 17: 83-91.
33. Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, Valat JP, Paintaud G, Goupille P,. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010; 32: 232-236.
34. Willot S, Vermeire S, Ohresser M, Rutgeerts P, Paintaud G, Belaiche J, De Vos M, Van Gossum A, Franchimont D, Colombel JF, Watier H, Louis E,. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics 2006; 16: 37-42.
35. Ducourau E, Ternant D, Lequerre T, Fuzibet P, Le Loet X, Watier H, Goupille P, Paintaud G, Vittecoq O, Mulleman D,. Towards an individualised target concentration of adalimumab in rheumatoid arthritis. Ann Rheum Dis 2014; 2014: 2013-204971.